Evotec stock trades at EUR 2.51, 2.87 percent above its low

Published on 10/13/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xetra closed at EUR 2.46 on October 12, 2026. Evotec stock costs EUR 2.51 on October 13, 2026, up 2.03 percent versus the Xetra close.

Key points in brief

Evotec stock trades at EUR 2.51, 2.87 percent above its 52-week low of EUR 2.44 on October 13, 2026.
The Xetra close was EUR 2.46 on October 12, 2026.
Evotec stock costs EUR 2.51 at Lang & Schwarz on October 13, 2026 at 12:53 p.m. CEST, up 2.03 percent versus the Xetra close of October 12, 2026.
Evotec is listed on Xetra and belongs to the TecDAX.

3D-Architekturvisualisierung eines modernen Glas-Forschungscampus mit begrüntem Innenhof — Architektur-Render eines modernen Forschungscampus veranschaulicht den Biotech-Standort von Evotec SE, ISIN DE0005664809, glasklar gestaltet, Illustration mit AI erstellt.

At Lang & Schwarz, Evotec stock was trading at EUR 2.51 on October 13, 2026 at 12:53 p.m. CEST, up 2.03 percent versus the Xetra close of EUR 2.46 on October 12, 2026. The price sits 2.87 percent above the 52-week low of EUR 2.44, making the recent low the key short-term reference for the shares.

Price remains near yearly low

The Xetra close of EUR 2.46 followed a sharp 11.13 percent decline on October 12, 2026, according to the dated Xetra market record published by FinanzNachrichten. The same listing record identifies Evotec with ticker EVT, ISIN DE0005664809 and the Xetra venue.

The current Lang & Schwarz price is 2.87 percent above the 52-week low, while the 52-week high stands at EUR 7.70. That places the stock 67.40 percent below its high, a wide range that keeps the latest intraday move in perspective.

Biotechnology listing and business model

Evotec is a biotechnology company that develops drug-discovery and pharmaceutical research services for partners. Its investor-relations page describes a model built around molecular data, disease models, omics-supported research and technology-driven drug development, with Just - Evotec Biologics as a major business pillar.

For investors, the price position matters because the stock is being assessed against a low of EUR 2.44 and a high of EUR 7.70 rather than a narrow trading band. The 65.00 percent gap between those two range points reflects a market that assigns a wide spread of outcomes to the company's research platforms and partnerships.

Evotec price and trading reference

The current quote was EUR 2.51 at Lang & Schwarz on October 13, 2026 at 12:53 p.m. CEST. The bid was EUR 2.51 and the ask was EUR 2.52, while the calculated gain against the Xetra close of EUR 2.46 on October 12, 2026 was EUR 0.05, or 2.03 percent.

Evotec's master-data record places the company in biotechnology and the TecDAX. The Xetra listing gives German investors a direct euro reference, while Lang & Schwarz provides the intraday indication used here. The next price checkpoint is whether the stock can hold above the EUR 2.44 52-week low in subsequent sessions.

The further course of trading is shown by the continuously updated real-time quote of Evotec stock.